Leverage is elevated, with total liabilities of $161.6M exceeding total assets of $128.3M and total debt of $106.6M producing negative equity of -$33.4M, though a current ratio of 1.44 and $110.8M in cash provide a near-term liquidity buffer.
Nanobiotix S.A. (NBTX) balance sheet — 15-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 |
|---|
| Total Current Assets | 123.43M | 62.75M | 61.47M | 87.34M | 52.36M | 93.06M | 125.25M | 46.13M | 42.65M | 53.11M | 26.89M | 22.95M | 35.5M | 6.89M | 13.54M | 2.33M |
| Cash & Short-Term Investments | 110.85M | 52.75M | 49.74M | 75.28M | 41.39M | 84.17M | 119.15M | 35.09M | 36.2M | 47.21M | 21.06M | 17M | 32.99M | 5M | 12.36M | 898.52K |
| Cash Only | 110.85M | 52.75M | 49.74M | 75.28M | 41.39M | 83.92M | 119.15M | 35.09M | 36.2M | 47.21M | 21.06M | 17M | 32.99M | 5M | 12.36M | 898.52K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 9.37M | 7.68M | 8.54M | 2.97M | 2.84M | 3.89M | 3.88M | 1.26M | 997K | 844K | 5.21K | 707.38K | 62.91K | 61.79K | 8.29K | 1.35M |
| Days Sales Outstanding | - | 94.57 | -433.28 | 29.91 | 217.2 | 537.02 | 608.36 | 180.42 | 104.6 | 82.77 | 0.35 | 64.3 | 8.29 | 14.13 | 3.12 | 361.3 |
| Inventory | 0 | 0 | 0 | 200K | 2.98M | 0 | 0 | 2.67M | 1.09M | -4.9M | -5.03M | 1.21M | 473.94K | 199.54K | -1.07M | 87.81K |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 2K | -1K | 6.33M | 2.17M | 3.04M | 0 | 4.43M | 5.33M | 4.73M | 5.02M | 4.66M | 2.04M | 1.69M | 0 | 0 |
| Total Non-Current Assets | 4.85M | 5.01M | 5.95M | 6.56M | 7.41M | 8.71M | 8.78M | 10.08M | 3.54M | 4.36M | 3.51M | 3.47M | 1.55M | 544.95K | 484.73K | 580.46K |
| Property, Plant & Equipment | 4.41M | 4.57M | 5.54M | 6.11M | 7.12M | 8.19M | 8.26M | 9.39M | 2.88M | 2.99M | 2.43M | 2.43M | 1.29M | 467.73K | 416.13K | 510.79K |
| Fixed Asset Turnover | 0.00x | 6.49x | -1.30x | 5.93x | 0.67x | 0.32x | 0.28x | 0.27x | 1.21x | 1.24x | 2.23x | 1.65x | 2.14x | 3.41x | 2.33x | 2.66x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 7K | 10K | 7K | 8K | 1K | 4K | 21K | 163K | 102K | 135.97K | 4.45K | 7.53K | 9.94K | 9.07K | 0 | 6.51K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 98K | 105K | 131K | 176K | 272.93K | 242.22K | 218.12K | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 433.82K | 434K | 406K | 443K | 291K | 421K | -1K | -1K | 382K | 0 | 0 | 0 | 247.35K | 68.14K | 68.6K | 63.16K |
| Total Assets | 128.28M | 67.76M | 67.42M | 93.9M | 59.77M | 101.77M | 134.03M | 56.2M | 46.2M | 57.47M | 30.4M | 26.42M | 37.05M | 7.44M | 14.02M | 2.91M |
| Asset Turnover | 0.00x | 0.44x | -0.11x | 0.39x | 0.08x | 0.03x | 0.02x | 0.05x | 0.08x | 0.06x | 0.18x | 0.15x | 0.07x | 0.21x | 0.07x | 0.47x |
| Asset Growth % | 108.39% | 0.51% | -28.2% | 57.1% | -41.27% | -24.07% | 138.47% | 21.67% | -19.61% | 89.02% | 15.08% | -28.7% | 398.12% | -46.96% | 381.38% | - |
| Total Current Liabilities | 85.9M | 57.51M | 58.94M | 49.87M | 37.94M | 36.84M | 19.04M | 14.35M | 11.6M | 9.35M | 8.25M | 7.1M | 4.42M | 3.28M | 2.16M | 1.41M |
| Accounts Payable | 6.16M | 6.58M | 4.48M | 6.7M | 4M | 5M | 5.57M | 6.15M | 4.54M | 5.14M | 4.37M | 3.59M | 2.23M | 1.35M | 279.36K | 399.82K |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Short-Term Debt | 32.05M | 3.1M | 3.66M | 3.82M | 3.6M | 7.08M | 3.67M | 500K | 500K | 770K | 1.08M | 1.07M | 320.97K | 231.04K | 360.31K | 295.44K |
| Deferred Revenue (Current) | 126.76M | 36.22M | 18.16M | 18.23M | 16.57M | 16.77M | 0 | 7.11M | 93K | 2.96M | 2.23M | 1.79M | 1.43M | 1.04M | 1.52M | 719.35K |
| Other Current Liabilities | 6.14M | 430K | 8.27M | 760K | 327K | 5.39M | 7.06M | -6.7M | 567K | 807.47K | 556.3K | -790.5K | -778.44K | -233.09K | 577.59K | 645.81K |
| Current Ratio | 1.44x | 1.09x | 1.04x | 1.75x | 1.38x | 2.53x | 6.58x | 3.22x | 3.68x | 5.68x | 3.26x | 3.23x | 8.03x | 2.10x | 6.27x | 1.65x |
| Quick Ratio | 1.44x | 1.09x | 1.04x | 1.75x | 1.30x | 2.53x | 6.58x | 3.03x | 3.58x | 6.20x | 3.87x | 3.06x | 7.92x | 2.04x | 6.76x | 1.59x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 75.75M | 94.74M | 74.19M | 45.87M | 48.88M | 38.13M | 44.52M | 43.77M | 20.36M | 4.19M | 4.76M | 3.7M | 2.31M | 974.93K | 1.17M | 573.18K |
| Long-Term Debt | 73.25M | 89.12M | 43.01M | 41.66M | 44.04M | 32.42M | 39.12M | 37.62M | 20.02M | 3.75M | 4.58M | 3.53M | 2M | 875.17K | 1.07M | 526.77K |
| Capital Lease Obligations | 8.51M | 1.89M | 2.97M | 3.88M | 4.57M | 5.39M | 4.99M | 5.81M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.23M | 3.73M | 28.21M | 325K | 270K | 318K | 414K | 332K | 334K | 446.27K | 175.21K | 173.91K | 312.33K | 99.77K | 95.37K | 46.41K |
| Total Liabilities | 161.65M | 152.24M | 133.12M | 95.74M | 86.81M | 74.98M | 63.56M | 58.11M | 31.95M | 13.54M | 13M | 10.81M | 6.74M | 4.26M | 3.33M | 1.99M |
| Total Debt | 106.57M | 95.32M | 50.9M | 50.56M | 53.17M | 46.02M | 48.98M | 44.53M | 20.52M | 4.73M | 5.67M | 4.6M | 2.32M | 1.11M | 1.43M | 822.21K |
| Net Debt | -4.28M | 42.57M | 1.17M | -24.72M | 11.78M | -37.9M | -70.17M | 9.43M | -15.68M | -42.48M | -15.39M | -12.4M | -30.66M | -3.9M | -10.93M | -76.31K |
| Debt / Equity | -3.19x | - | - | - | - | 1.72x | 0.70x | - | 1.44x | 0.11x | 0.33x | 0.29x | 0.08x | 0.35x | 0.13x | 0.89x |
| Debt / EBITDA | -1.52x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.06x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -3.12x | -1.30x | -8.44x | -3.04x | -7.83x | -67.43x | -109.96x | -9.76x | -35.50x | -233.15x | -213.84x | -288.01x | -172.63x | -332.90x | -66.92x | -169.52x |
| Total Equity | -33.37M | -84.48M | -65.7M | -1.84M | -27.05M | 26.79M | 70.47M | -1.91M | 14.24M | 43.92M | 17.4M | 15.61M | 30.32M | 3.18M | 10.7M | 925.53K |
| Equity Growth % | -3656.67% | -28.58% | -3463.07% | 93.18% | -200.95% | -61.98% | 3791.36% | -113.4% | -67.57% | 152.45% | 11.45% | -48.5% | 852.78% | -70.25% | 1055.72% | - |
| Book Value per Share | -0.68 | -1.77 | -1.39 | -0.05 | -0.78 | 0.77 | 2.89 | -0.09 | 0.73 | 2.51 | 1.14 | 1.10 | 2.36 | 0.30 | 1.30 | 0.60 |
| Total Shareholders' Equity | -33.37M | -84.48M | -65.7M | -1.84M | -27.05M | 26.79M | 70.47M | -1.91M | 14.24M | 43.92M | 17.4M | 15.61M | 30.32M | 3.18M | 10.7M | 925.53K |
| Common Stock | 1.52M | 1.45M | 1.42M | 1.41M | 1.05M | 1.04M | 1.03M | 672K | 589K | 589K | 478.96K | 424.97K | 421.94K | 322.87K | 322.57K | 230.32K |
| Retained Earnings | 0 | -23.96M | -68.13M | -39.7M | -57.04M | -47M | -33.59M | -50.91M | -30.34M | -26.14M | -21.88M | -17M | -9.56M | -8.14M | -5.33M | -5.25M |
| Treasury Stock | -227.91K | -228K | -228K | -228K | -228K | -202K | -196K | -169K | -124K | -27K | -57.77K | -81.88K | -74.49K | -221.66K | -195.21K | 0 |
| Accumulated OCI | -431.37M | -376.14M | -311.51M | -276.07M | -226.58M | -182.82M | -152.51M | -104.64M | -78.68M | -54.28M | -35.44M | -20.36M | -12.32M | -4.33M | 385.57K | -9.66M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying NBTX stock.
As of 2025, Nanobiotix S.A. (NBTX) had total assets of $67.8M including $62.8M in current assets.
Nanobiotix S.A. (NBTX) carries total debt of $95.3M, offset by $52.8M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Nanobiotix S.A. (NBTX) has total shareholders' equity (book value) of $-84.5M ($-1.77 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Nanobiotix S.A. (NBTX) reported a current ratio of 1.09x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Negative equity and cash dependence
Balance Sheet Oscillating Without Durable Repair
According to reported quarterly figures, NBTX's equity swung from a $26.8M surplus in 2021Q4 to a deficit of -$33.4M in 2026Q2, with total liabilities consistently exceeding total assets in most recent periods and no sustained strengthening trend visible.
The pattern suggests the balance sheet has repeatedly been repaired by external inflows and then eroded again by operating losses, rather than strengthening through retained operating profits. Retained earnings remain deeply negative across the window, with the sharp swings in 2024 and 2023 pointing to large non-recurring or milestone-linked movements. Investors should monitor whether the 2026Q2 cash rebuild to $110.8M is sustained or reflects timing of partner-linked receipts.
Debt Load Exceeds Equity Cushion
Based on reported figures, NBTX carried total debt of $106.6M in 2026Q2 against negative equity of -$33.4M, a position where liabilities of $161.6M dwarf the asset base and leave little margin for error on repayment or refinancing.
With debt roughly tripling from $45.1M in 2022Q2 to $106.6M, leverage appears to be expanding faster than the operating base can support, which may reflect necessity-driven rather than strategic borrowing. The negative equity position means debt is not covered by book value, so repayment depends almost entirely on continued access to capital or partner cash. Refinancing terms and maturity schedules are not disclosed in the supplied data and warrant further investigation.
Cash Buffer Thin Against Sustained Burn
As reported in financial statements, NBTX's cash of $110.8M against a current ratio of 1.44 in 2026Q2 provides a near-term buffer, but cash has fluctuated between $21.6M and $83.9M across the window, underscoring dependence on lumpy inflows.
Given quarterly operating cash burn of roughly $22M and free cash flow near -$23M, the reported cash balance covers only a limited number of quarters at current consumption rates. The current ratio improved sharply from 0.63 in 2025Q2 to 1.44 in 2026Q2, which appears driven by a cash rebuild rather than structural working-capital strength. Liquidity headroom therefore looks adequate in the near term but sensitive to the timing of milestone receipts.
Deferred Revenue Anchors Near-Term Recognition
Based on EDBL-style reported figures, NBTX's deferred revenue of $36.2M in 2026Q2, unchanged since 2025Q2, suggests a sizable contracted obligation still being recognized, though the lack of movement signals slow conversion of partner payments into revenue.
A flat deferred revenue balance over several quarters may indicate that recognized revenue is drawing down slowly against previously received upfront cash. This leaves the reported revenue run-rate dependent on the pace of performance obligations that are not quantified in the supplied data. Remaining performance obligation disclosure is absent, so the forward revenue visibility cannot be assessed with confidence.
Cash Rebound May Mask Structural Deficit
Based on reported figures, the 2026Q2 cash increase to $110.8M and current ratio of 1.44 could be read as balance sheet recovery, while negative equity, rising debt, and persistent operating losses point to a structurally strained position.
The headline liquidity improvement may reflect timing of partner-linked receipts rather than a durable change in cash generation, since free cash flow remained negative in the same quarter. Stripping out the cash rebuild, the underlying position of liabilities exceeding assets and debt approaching $107M appears unchanged. Investors should treat the improved current ratio with caution until operating cash flow turns sustainably positive.